Stryker Co. (NYSE:SYK) is Gouws Capital LLC’s 7th Largest Position

Gouws Capital LLC grew its position in shares of Stryker Co. (NYSE:SYK) by 0.5% during the 4th quarter, Holdings Channel.com reports. The institutional investor owned 20,014 shares of the medical technology company’s stock after buying an additional 90 shares during the quarter. Stryker accounts for 4.9% of Gouws Capital LLC’s holdings, making the stock its 7th biggest position. Gouws Capital LLC’s holdings in Stryker were worth $7,206,000 at the end of the most recent reporting period.

Several other institutional investors also recently modified their holdings of the business. Creative Financial Designs Inc. ADV grew its stake in Stryker by 19.6% in the 3rd quarter. Creative Financial Designs Inc. ADV now owns 317 shares of the medical technology company’s stock valued at $114,000 after purchasing an additional 52 shares during the period. Janney Montgomery Scott LLC boosted its holdings in shares of Stryker by 0.8% in the 3rd quarter. Janney Montgomery Scott LLC now owns 64,555 shares of the medical technology company’s stock worth $23,321,000 after buying an additional 517 shares during the last quarter. PDS Planning Inc grew its position in Stryker by 5.5% during the third quarter. PDS Planning Inc now owns 1,422 shares of the medical technology company’s stock valued at $514,000 after buying an additional 74 shares during the period. Moloney Securities Asset Management LLC purchased a new stake in Stryker during the third quarter worth about $1,133,000. Finally, FSM Wealth Advisors LLC raised its position in Stryker by 2.8% in the third quarter. FSM Wealth Advisors LLC now owns 1,888 shares of the medical technology company’s stock worth $682,000 after acquiring an additional 52 shares during the period. 77.09% of the stock is owned by institutional investors.

Insider Transactions at Stryker

In other Stryker news, Director Allan C. Golston sold 2,458 shares of Stryker stock in a transaction dated Tuesday, February 18th. The stock was sold at an average price of $383.07, for a total transaction of $941,586.06. Following the completion of the sale, the director now owns 14,895 shares of the company’s stock, valued at $5,705,827.65. The trade was a 14.16 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, Director Ronda E. Stryker sold 201,392 shares of the firm’s stock in a transaction dated Friday, January 31st. The shares were sold at an average price of $392.24, for a total value of $78,993,998.08. Following the transaction, the director now directly owns 3,642,075 shares in the company, valued at approximately $1,428,567,498. This represents a 5.24 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders own 5.90% of the company’s stock.

Stryker Trading Down 1.2 %

Shares of SYK stock opened at $390.27 on Wednesday. The company has a market capitalization of $148.92 billion, a PE ratio of 50.29, a price-to-earnings-growth ratio of 2.93 and a beta of 0.96. Stryker Co. has a 52-week low of $314.93 and a 52-week high of $406.19. The business’s fifty day moving average is $381.45 and its 200 day moving average is $372.28. The company has a debt-to-equity ratio of 0.59, a quick ratio of 1.32 and a current ratio of 1.95.

Stryker (NYSE:SYK) last released its quarterly earnings results on Tuesday, January 28th. The medical technology company reported $4.01 earnings per share for the quarter, beating the consensus estimate of $3.87 by $0.14. Stryker had a return on equity of 23.58% and a net margin of 13.25%. During the same period in the previous year, the company posted $3.46 EPS. On average, equities research analysts anticipate that Stryker Co. will post 13.47 EPS for the current fiscal year.

Stryker Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Wednesday, April 30th. Shareholders of record on Monday, March 31st will be paid a $0.84 dividend. The ex-dividend date is Monday, March 31st. This represents a $3.36 dividend on an annualized basis and a yield of 0.86%. Stryker’s dividend payout ratio is presently 43.30%.

Analysts Set New Price Targets

SYK has been the subject of several research analyst reports. Argus set a $450.00 price target on shares of Stryker in a research note on Monday, February 3rd. JPMorgan Chase & Co. raised their target price on Stryker from $420.00 to $445.00 and gave the stock an “overweight” rating in a research report on Wednesday, January 29th. Truist Financial upped their price target on Stryker from $409.00 to $413.00 and gave the company a “hold” rating in a research report on Thursday, January 30th. Needham & Company LLC reissued a “buy” rating and issued a $442.00 price objective on shares of Stryker in a report on Wednesday, January 29th. Finally, The Goldman Sachs Group upped their price objective on shares of Stryker from $384.00 to $427.00 and gave the company a “neutral” rating in a report on Thursday, January 30th. Five analysts have rated the stock with a hold rating and sixteen have assigned a buy rating to the company. Based on data from MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus target price of $422.15.

Stryker Profile

Stryker Corporation operates as a medical technology company. The company operates through two segments, MedSurg and Neurotechnology, and Orthopaedics and Spine. The Orthopaedics and Spine segment provides implants for use in total joint replacements, such as hip, knee and shoulder, and trauma and extremities surgeries.